Cabazitaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Drug Profile

Cabazitaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: Cabazitaxel lipid suspension

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Sep 2015 Intas Pharmaceuticals and Jina Pharmaceuticals collaborated in the development of Nanoaqualip™ technology
  • 05 Jun 2015 Preclinical trials in Cancer in India (IV) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top